Oncology Institute Inc’s recently made public that its Director M33 Growth I L.P. unloaded Company’s shares for reported $2.05 million on Jun 05 ’25. In the deal valued at $3.05 per share,673,676 shares were sold. As a result of this transaction, M33 Growth I L.P. now holds 13,950,557 shares worth roughly $34.04 million.
Then, M33 Growth I L.P. sold 76,324 shares, generating $232,788 in total proceeds. Upon selling the shares at $3.05, the Director now owns 1,272,724 shares.
Before that, Hively Brad sold 1,976,137 shares. Oncology Institute Inc shares valued at $5,672,106 were divested by the Director at a price of $2.87 per share. As a result of the transaction, Hively Brad now holds 603,501 shares, worth roughly $1.47 million.
BTIG Research initiated its Oncology Institute Inc [TOI] rating to a Buy in a research note published on May 15, 2025; the price target was $7. Guggenheim began covering TOI with “Buy” recommendation on September 14, 2022. Jefferies started covering the stock on August 15, 2022. It rated TOI as “a Buy”.
Price Performance Review of TOI
On Monday, Oncology Institute Inc [NASDAQ:TOI] saw its stock fall -1.21% to $2.44. Over the last five days, the stock has lost -6.15%. Oncology Institute Inc shares have risen nearly 689.64% since the year began. Nevertheless, the stocks have risen 358.56% over the past one year. While a 52-week high of $3.50 was reached on 04/24/25, a 52-week low of $0.13 was recorded on 01/10/25.
Levels Of Support And Resistance For TOI Stock
The 24-hour chart illustrates a support level at 2.40, which if violated will result in even more drops to 2.36. On the upside, there is a resistance level at 2.52. A further resistance level may holdings at 2.60.
